Literature DB >> 31794865

Reduced PD-1 expression on circulating follicular and conventional FOXP3+ Treg cells in children with new onset type 1 diabetes and autoantibody-positive at-risk children.

Andrea Vecchione1, Roberta Di Fonte2, Jolanda Gerosa1, Tatiana Jofra1, Maria Pia Cicalese3, Vincenzo Napoleone4, Elio Ippolito1, Giuseppe Galvani1, Francesca Ragogna1, Angela Stabilini1, Eleonora Bianconi5, Pauline Grogan6, Clara Bonura7, Riccardo Bonfanti8, Giulio Frontino7, Rita Nano1, Raffaela Melzi1, Maurizio De Pellegrin9, Andrea Laurenzi10, Franco Meschi7, Graziano Barera7, Andrea Rigamonti7, Rita Indirli11, Emanuele Bosi12, Lorenzo Piemonti13, Alessandro Aiuti3, Manuela Battaglia14, Georgia Fousteri15.   

Abstract

Autoantibodies (AAbs) are a hallmark of Type 1 diabetes (T1D). Alterations in the frequency and phenotype of follicular helper (Tfh) T cells have been previously documented in patients with type 1 diabetes (T1D), but the contribution of follicular regulatory T (Treg) cells, which are responsible for suppressing AAb development, is less clear. Here, we investigated the frequency and activation status of follicular (CXCR5+) and conventional (CXCR5-) Treg cells in the blood of children with new-onset T1D, and children with risk for developing T1D (AAb-positive) and compared them to AAb-negative controls. Blood follicular and conventional Treg cells were higher in frequency in children with new onset T1D, but expressed reduced amounts of PD-1 as compared to AAb-negative children. Interestingly, the proportion of circulating FOXP3+ Tregs expressing PD-1 was also reduced in AAb-positive at-risk children as compared to AAb-negative controls, suggesting its potential use as a biomarker of disease progression. Follicular Treg cells were reduced in frequency in the spleens of prediabetic NOD mice as they became older and turned diabetic. Interestingly, PD-1 expression declined also on circulating follicular and conventional Treg cells in prediabetic NOD mice as they aged. Together, these findings show that the frequency of circulating follicular and conventional Treg cells and their levels of PD-1 change with disease progression in children at-risk for developing T1D and in NOD mice.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AAb-negative; AAb-positive; Autoantibodies (AAb); CXCL13; Follicular Treg cells; PD-1; Regulatory T cells (Treg); Tfh cells; Type 1 diabetes (T1D)

Year:  2019        PMID: 31794865     DOI: 10.1016/j.clim.2019.108319

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  9 in total

1.  Reduced Follicular Regulatory T Cells in Spleen and Pancreatic Lymph Nodes of Patients With Type 1 Diabetes.

Authors:  Andrea Vecchione; Tatiana Jofra; Jolanda Gerosa; Kimberly Shankwitz; Roberta Di Fonte; Giuseppe Galvani; Elio Ippolito; Maria Pia Cicalese; Andrew R Schultz; Howie R Seay; Mariagrazia Favellato; Giulia Milardi; Angela Stabilini; Francesca Ragogna; Pauline Grogan; Eleonora Bianconi; Andrea Laurenzi; Amelia Caretto; Rita Nano; Raffaela Melzi; Nichole Danzl; Emanuele Bosi; Lorenzo Piemonti; Alessandro Aiuti; Todd Brusko; Constantinos Petrovas; Manuela Battaglia; Georgia Fousteri
Journal:  Diabetes       Date:  2021-10-07       Impact factor: 9.461

2.  T1D patient-derived hematopoietic stem cells are programmed to generate Tph, Tfh, and autoimmunity-associated B cell subsets in human immune system mice.

Authors:  Andrea Vecchione; Rachel Madley; Nichole Danzl; Chiara Borsotti; Mohsen Khosravi Marharlooei; Hao-Wei Li; Grace Nauman; Xiaolan Ding; Siu-Hong Ho; Georgia Fousteri; Megan Sykes
Journal:  Clin Immunol       Date:  2022-05-26       Impact factor: 10.190

3.  Deep immune phenotyping reveals similarities between aging, Down syndrome, and autoimmunity.

Authors:  Katharina Lambert; Keagan G Moo; Azlann Arnett; Gautam Goel; Alex Hu; Kaitlin J Flynn; Cate Speake; Alice E Wiedeman; Vivian H Gersuk; Peter S Linsley; Carla J Greenbaum; S Alice Long; Rebecca Partridge; Jane H Buckner; Bernard Khor
Journal:  Sci Transl Med       Date:  2022-01-12       Impact factor: 19.319

4.  uPAR+ extracellular vesicles: a robust biomarker of resistance to checkpoint inhibitor immunotherapy in metastatic melanoma patients.

Authors:  Letizia Porcelli; Michele Guida; Simona Serratì; Amalia Azzariti; Simona De Summa; Roberta Di Fonte; Ivana De Risi; Marianna Garofoli; Mariapia Caputo; Antonio Negri; Sabino Strippoli
Journal:  J Immunother Cancer       Date:  2021-05       Impact factor: 13.751

Review 5.  Role of the CXCL13/CXCR5 Axis in Autoimmune Diseases.

Authors:  Zijian Pan; Tong Zhu; Yanjun Liu; Nannan Zhang
Journal:  Front Immunol       Date:  2022-03-04       Impact factor: 7.561

6.  Severe Immune-Related Adverse Events in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma Are Associated with PDCD1 Polymorphism.

Authors:  Mizuki Kobayashi; Kazuyuki Numakura; Shingo Hatakeyama; Yumina Muto; Yuya Sekine; Hajime Sasagawa; Soki Kashima; Ryohei Yamamoto; Atsushi Koizumi; Taketoshi Nara; Mitsuru Saito; Shintaro Narita; Chikara Ohyama; Tomonori Habuchi
Journal:  Genes (Basel)       Date:  2022-07-05       Impact factor: 4.141

7.  Editorial: Follicular Helper T Cells in Immunity and Autoimmunity.

Authors:  Maria Pia Cicalese; Shahram Salek-Ardakani; Georgia Fousteri
Journal:  Front Immunol       Date:  2020-05-29       Impact factor: 7.561

Review 8.  Role of the PD-1/PD-L1 Dyad in the Maintenance of Pancreatic Immune Tolerance for Prevention of Type 1 Diabetes.

Authors:  Marika Falcone; Georgia Fousteri
Journal:  Front Endocrinol (Lausanne)       Date:  2020-08-19       Impact factor: 5.555

9.  Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma.

Authors:  Simona Serratì; Michele Guida; Letizia Porcelli; Amalia Azzariti; Roberta Di Fonte; Simona De Summa; Sabino Strippoli; Rosa Maria Iacobazzi; Alessandra Quarta; Ivana De Risi; Gabriella Guida; Angelo Paradiso
Journal:  Mol Cancer       Date:  2022-01-18       Impact factor: 27.401

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.